A Phase II Trial of Axicabtagene Ciloleucel with Radiation Therapy in Relapsed/Refractory Follicular Lymphoma
Phase 2
20
about 4.7 years
18+
1 site in TX
About this study
This trial is testing the safety of axicabtagene ciloleucel, a type of drug, given with radiation therapy to people whose follicular lymphoma has returned or not responded to previous treatments. The goal is to see how safe this combination treatment is.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Acetaminophen
- 2.Take Axicabtagene Ciloleucel
- 3.Take Cyclophosphamide
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
paracetamol (Reduces fever and pain (mechanism not fully understood)), axicabtagene ciloleucel, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), diphenhydramine, Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), prednisone
oral, infusion, injection (Injection)
Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Oncology